-
BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy
•
BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120 subjects in the Phase II clinical study for its small molecule ETA receptor antagonist, SC0062, in the IgA nephropathy cohort. The study, which first dosed in June 2023, marks a significant milestone in the development…
-
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
•
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The collaboration aims to conduct a Phase Ib/II study assessing the safety and efficacy of BioCity’s BC3402 in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of advanced hepatocellular cell…
